Apitegromab Prevents Muscle Loss From GLP-1 Therapy
An investigational drug called apitegromab reduces lean muscle loss in patients using GLP-1 receptor agonists. Researchers published these findings…
-
-
Skin Care On GLP-1: How To Protect And Firm Skin During And After Rapid Weight Loss
Glucagon-like peptide-1 receptor agonists have significantly changed how we manage obesity and type 2 diabetes. Medications like Ozempic, Wegovy,…
-
Pre-Pregnancy GLP-1 Therapy and Gestational Diabetes: Why Discontinuation Timing Matters
Glucagon-like peptide-1 receptor agonists and tirzepatide have changed how we manage obesity and type 2 diabetes. As a result,…
-
GLP-3 Versus GLP-1: A Clinical Comparison for Weight Loss Management
Clinicians and patients often come across the term GLP-3 when discussing new obesity treatments. This term does not have…
-
8 Common GLP-1 Sexual Side Effects Explained
GLP-1 receptor agonists have changed weight management and blood sugar control for millions of patients. Most clinical focus tends…
-
How to Exercise on GLP-1 Medications: A Clinical Guide
Glucagon-like peptide-1 receptor agonists have changed the way we treat obesity and type 2 diabetes. Medications like semaglutide and…
-
Do GLP-1 Receptor Agonists Alter Personality and Emotional Function?
Demand for weight loss medications is at an all-time high. National survey data show that about half of adults…
-
Switching From Injectable to Oral GLP-1s for Weight Loss: Five Tips for a Smoother Transition
Glucagon-like peptide-1 receptor agonists have changed how we treat obesity and weight management. Traditionally, medications like Wegovy and Ozempic…
-
Medicare’s New GLP-1 Bridge Program: Seven Essential Clinical and Coverage Facts
Medicare made a notable policy change on July 1 by extending limited coverage for weight management medications through the…
-
Medicare Is Opening the Door Wider for Eli Lilly’s Weight Loss and Diabetes Drugs
Eli Lilly’s latest earnings report caught the attention of analysts and patients alike. The drugmaker reported $19.8 billion in…
